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Abstract. The recent synthesis of fentanyl derivatives, 
some of which appear to have novel profiles of pharmaco- 
logical effects, has provided compelling evidence that la 
opioid efficacy might be altered systematically by modifi- 
cations in the parent compound fentanyl. In the present 
study a new 4-(heteroanilido)-piperidine, compound 28, 
was studied for its effects in rhesus monkeys. In self- 
administration studies compound 28 maintained rates of 
lever pressing similar to those maintained by alfentanil; 
the reinforcing effects of compound 28 were attenuated by 
the opioid antagonist quadazocine. In drug discrimina- 
tion studies compound 28 did not substitute for the ~c 
agonist ethylketocyclazocine and did substitute for the 
agonist alfentanil. In morphine-treated subjects discrimin- 
ating between saline and naltrexone, compound 28 did 
not substitute for naltrexone; however, in morphine-absti- 
nent subjects compound 28 reversed naltrexone lever 
responding. Moreover, this discriminative stimulus effect 
in morphine-abstinent subjects was antagonized by nal- 
trexone and by quadazocine in a manner consistent with 
receptor mediation. Compound 28 also was an effective 
analgesic in a warm-water, tail-withdrawal procedure and 
it decreased markedly respiratory function. The analgesic 
effects as well as the respiratory depressant effects of 
compound 28 were antagonized by quadazocine. To- 
gether, these results show compound 28 to be a potent, 
efficacious ~t agonist of similar potency to alfentanil. Large 
differences in apparent efficacy at ~t receptors between 
compound 28 and another compound in this series (mir- 
fentanil), clearly demonstrate that, within this chemical 
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family, small chemical changes can confer significant dif- 
ferences in pharmacologic effect. 
Key words: Opioid Drug discrimination Analgesia - 
Fentanyl Rhesus monkey Competitive antagonism - 
Respiratory function - Self administration 
Bagley and colleagues (Bagley et al. 1989) reported on a 
novel series of fentanyl derivatives, some of which dis- 
played opioid antagonist actions under some conditions. 
That study provided the first evidence of opioid antagon- 
ist action for a compound in the fentanyl (i.e., 4-[heteroan- 
ilido]piperidine) series. One compound in this series, mir- 
fentanil (compound 32 in Bagley et al. 1989), has been 
studied for its effects in vitro and in vivo and has been 
shown to have a novel pharmacological profile (Aeeto 
et al. 1990; France et al. 1990b, 1991; Ossipov et al. 1990; 
Woods et al. 1990). For  example, as compared to fentanyl, 
mirfentanil appears to have relatively low efficacy at ~t 
opioid receptors, exerting agonist actions under some 
conditions and antagonist actions under other conditions. 
The limited opioid efficacy of mirfentanil was evident 
under a variety of conditions in rodents and in primates. 
Other effects of mirfentanil appear to differ qualitat- 
ively among species. For  example, there was no evidence 
of nonopioid actions for mirfentanil in rodents (Bagley et 
al. 1989), whereas in rhesus monkeys mirfentanil had 
analgesic effects that did not appear to be mediated by 
opioid receptors (France et al. 1991). The mechanism of 
this nonopioid analgesic action for mirfentanil has not 
been established; moreover, it is not yet clear why some of 
the effects of mirfentanil are different among rodents, 
pigeons and primates. Nevertheless, it appears as though 
further studies on this chemical series might be parti- 
cularly useful for characterizing the structural 
requirements that contribute to differences in opioid 
efficacy. 
A second compound in this chemical series, compound 
28 (Fig. 1), also appeared to have a profile of pharmacolo- 
gical effects in rodents that was different from the parent 
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Fig. 1. Structures of fentanyl, 
alfentanil, mirfentanil and 
compound 28 
rabbi t s  c o m p o u n d  28 an tagon ized  bo th  the analgesic  
effects and  the r e sp i ra to ry  depressant  effects of morphine .  
When  s tudied  for agonis t  act ions,  c o m p o u n d  28 was 
effective in some ( rabbi t  too th  pulp,  ra t  tail  flick) but  not  
all (rat hot  plate,  mouse  hot  plate) analges ia  assays. 
Toge ther  these da t a  suggested that ,  l ike mirfentanil ,  com-  
p o u n d  28 might  have relat ively low efficacy as an op io id  
agonist ,  and  therefore might  be a novel  op io id  with 
therapeut ic  potent ia l .  As with mirfentanil ,  there was no 
suggest ion f rom roden t  s tudies tha t  c o m p o u n d  28 might  
have n o n o p i o i d  actions. 
The purpose  of the present  s tudy was to character ize  
c o m p o u n d  28 in vivo under  exper imenta l  condi t ions  tha t  
have been used extensively for assessing op io id  agonis ts  
and  antagonis ts ,  inc luding ano the r  fentanyl  derivative,  
mirfentani l  (e.g., F r ance  et al. 1990b). The  results  of the 
present  s tudies demons t r a t e  that ,  in cont ras t  to  the low 
efficacy op io id  act ions  and n o n o p i o i d  analgesic  act ions  
repor ted  previous ly  for mirfentanil ,  c o m p o u n d  28 is a 
highly efficacious, g-selective op io id  with no a p p a r e n t  
n o n o p i o i d  ac t ions  in rhesus monkeys .  
Materials and methods 
Subjects 
Seventeen adult male and female rhesus monkeys (Macaca mulatta) 
were housed individually with free access to water. Subjects that 
discriminated between saline and either alfentanil or ethylketocyc- 
lazocine (EKC) were maintained at 85% of their free-feeding body 
weights by food received in experimental sessions and post-session 
feeding (Purina Monkey Chow) in the home cage; other subjects had 
free access to Purina Monkey Chow. All subjects received fresh fruit 
several times per week. In addition, subjects in the self-administra- 
tion study had chronic, indwelling intravenous (IV) catheters; sub- 
jects discriminating between saline and naltrexone were treated daily 
with morphine. All subjects used in these studies had previously 
received various opioid agonists and antagonists. 
Apparatus 
For self-administration studies, subjects were housed in stainless 
steel cages measuring 83 x 76 x 51 cm (Woods 1980; Winger et aI. 
1989); in each cage was a stainless steel panel (15.4x 15.4cm) 
equipped with two response levers and three stimulus lights. A 
tubular stainless steel harness was connected to a hollow, jointed 
restraining arm that carried the cannula from the exit site at the 
midscapular region to the rear of the cage; the catheter was connec- 
ted to an infusion pump (Watson-Marlow, Co., Model MHRK 55, 
Falmouth, UK) located behind the cage. 
For analgesia studies, drug discrimination studies, and studies 
on respiratory function, rhesus monkeys were seated in primate 
chairs that provided minimal restraint at the neck and waist. During 
drug discrimination and respiration studies the chairs were located 
in a sound-attenuating, ventilated chamber. For drug discrimination 
studies two response levers and a food receptacle were located 
within reach of a seated monkey. An array of stimulus lights located 
above the response levers indicated schedule conditions (see Proced- 
ure). In addition, some chambers were equipped with a pair of shoes 
containing brass electrodes; electric shock could be delivered to the 
electrodes by an a.c. shock generator located in an adjacent room. 
Experimental events were controlled and data recorded with IBM 
PCjr microprocessors. 
Thermos bottles containing 40, 50, or 55°C water were used to 
study tail withdrawal latencies. A pushbutton switch was connected 
to a microprocessor used to measure and record latencies. 
A closed-chamber head plethysmograph was placed over the 
subject's head for'studies of respiratory function. Plastic neck plates, 
several rubber dams, and sealant were used to reduce gas leakage 
from the helmet. Air or 5% CO2 in air was pumped into the 
plethysmograph and removed by a vacuum pump (101/rain). A 
pressure transducer detected changes in air flow resulting from 
inspiration and expiration; with a microprocessor pressure changes 
were translated analog-to-digital and transformed according to 
known standards to fiequency of respiration (f; inspirations/min) 
and volume of respiration (VT; tidal volume). 
Procedure 
Self administration studies, Procedures used to assess positive re- 
inforcing effects of opioids have been described previously (Winger 
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et al. 1989). Experimental sessions were conducted twice daily with 
each session comprised of four, discrete components. During each of 
the four components a red stimulus light was illuminated and IV 
infusions (drug or vehicle) were available under a fixed ratio (FR) 30 
schedule. Each tV infusion was followed by a 45-s timeout during 
which stimulus lights were extinguished and lever presses had no 
programmed consequence. Components were separated by a 10-rain 
timeout. A component ended after 25 min or 20 infusions, whichever 
occurred first; thus, the maximum session length was 130 rain [(4 
x 25-min component) + (3 x 10-min timeout)]. Responses on a sec- 
ond lever had no programmed consequence. 
A different dose of drug was available in each of the four 
components. The order in which doses were presented within a 
session was either ascending, descending or mixed (e.g., 0.001, 0.01, 
0.00032, 0.0032 mg/kg/injection); the presentation of different dose 
orders varied randomly among sessions with the same dose order 
never presented for more than two consecutive sessions. Variations 
in the dose administered corresponded to changes in the infusion 
duration for a fixed concentration of drug (e.g., 5-s infusion 
= 0.0001 mg/kg/injection of alfentanil; 16.7-s infusion 
= 0.00032 mg/kg/injection of alfentanil). Drug-maintained lever 
pressing was considered stable and adequate for testing when the 
rate of lever pressing was dose-related for alfentanil, when at least 
one dose of alfentanil maintained response rates of at least one 
response per second, and when the substitution of saline resulted in 
response rates less than 0.5 responses per second. Compound 28 was 
studied from doses that produced responding similar to that pro- 
duced by saline substitution to doses that produced rates of lever 
pressing _> 1 response per second. In other studies, a single IV 
infusion of the opioid antagonist quadazocine was administered 
30 rain prior to the beginning of a dose-effect determination with 
compound 28. 
Discrimination studies. Discriminative stimulus eflbcts of compound 
28 were assessed in three, separate groups of rhesus monkeys. One 
group of monkeys discriminated between 0.0056 mg/kg alfentanil 
and saline; a second group of monkeys discriminated between 
0.0032 mg/kg EKC and saline; a third group of monkeys was 
treated daily with morphine (3.2 mg/kg/day) 3 h prior to experi- 
mental sessions and discriminated between 0.01 mg/kg naltrexone 
and saline. Subjects in the alfentanil and EKC groups responded 
under FR schedules of food presentation and subjects in the naltrex- 
one discrimination group responded under an FR schedule of 
stimulus-shock termination. 
Daily training sessions consisted of several (1-6) discrete, 15-min 
cycles with each cycle comprised of a 10-min timeout, during which 
lever presses had no programmed consequence, and a 5-rain re- 
sponse period, during which stimulus lights were illuminated and a 
schedule of food presentation (alfentanil and EKC groups) or stimu- 
lus-shock termination (naltrexone group) was in effect. Under the 
food schedule subjects could receive a food pellet (300 mg banana- 
flavored; P.L Noyes Co., Lancaster, NH) by making 20 (alfentanil 
group) or 30 (EKC group) consecutive responses on the lever 
designated correct according to the injection given during the 
timeout of that cycle (left lever, saline; right lever, alfentanil or EKC). 
Under the stimulus-shock termination schedule subjects could post- 
pone scheduled shocks for 30 s and terminate a shock-associated 
visual stimulus by responding 5 times consecutively on the lever 
designated correct according to the injection given during the 
fimeout of that cycle (left lever, saline; right lever, naltrexone). Under 
the schedule of stimulus-shock termination, failure to satisfy the 
response requirement within t5 s resulted in the delivery of a brief 
electric shock. For subjects responding under the food presentation 
schedule, stimulus lights were extinguished after 5 rain or ten food 
presentations, whichever occurred first. For subjects responding 
under the stimulus-shock termination schedule, stimulus lights were 
extinguished after 5 rain or the delivery of four shocks, whichever 
occurred first. For all subjects the interinjection interval was 15 min 
and, during training sessions, responses on the incorrect lever reset 
the response requirement on the correct lever. For some training 
sessions the cycle during which drug was administered was preceded 
by one or more saline-injection cycles during which only responding 
on the left lever resulted in food delivery or postponement of the 
shock schedule. For other training sessions saline was administered 
during the timeout of all cycles. 
Test sessions were identical to training sessions, except that 
subjects could receive food or postpone scheduled shocks by satis- 
fying the FR requirement on either lever, and increasing doses of 
drug were administered during the timeout of consecutive cycles 
such that the cumulative dose increased by 0.5 or 0.25 log units per 
cycle. Compound 28 was studied up to doses that either substituted 
completely for a training drug (alfentanil, EKC or naltrexone) or to 
doses that decreased substantially rates of lever pressing. Other 
studies in morphine-treated monkeys discriminating between nal- 
trexone and saline further characterized the opioid agonist actions of 
compound 28. Specifically, compound 28 was studied in morphine- 
abstinent (i.e., saline-treated) monkeys for its ability to attenuate 
naltrexone lever responding. Because compound 28 attenuated nal- 
trexone-lever responding in morphine-abstinent subjects (see Res- 
ults), other studies examined possible antagonism of this effect by the 
opioid antagonists naltrexone and quadazocine. For antagonism 
studies, subjects received saline 3 h prior to an experimental session 
during which a dose of opioid antagonist was administered on the 
first cycle and increasing doses of compound 28 were administered 
on subsequent cycles. 
Analgesia sludies. Procedures used to assess analgesic effects in 
rhesus monkeys have been described previously (Dykstra and 
Woods 1986). Experimental sessions consisted of several discrete 30- 
min components with each component comprised of a 20-rain 
timeout, during which subjects were not handled or disturbed, and a 
10-rain assessment period during which the latency for subjects to 
remove their tails from warm water was determined for 40, 50 and 
55 ° C water. For tail withdrawal tatencies the lower 10-15 cm of the 
shaved tail was immersed in a thermos containing water; if the 
subject failed to remove its tail within 20 s the experimenter removed 
the thermos and a latency of 20 s was recorded for that subject. 
Increasing doses of drug were administered during the first minute of 
consecutive timeouts with the cumulative dose increasing by 0.5 log 
units per cycle. To determine whether analgesic effects of compound 
28 were mediated by opioid receptors, a dose-effect determination 
was repeated for compound 28 beginning 30 min alter SC adminis- 
tration of the opioid antagonist quadazocine. 
Respiration studies. Procedures for assessing effects of drugs on 
respiratory function in rhesus monkeys have been described pre- 
viously (Howell et at. 1988). Sessions consisted of several discrete, 30- 
min cycles with each cycle comprised of a 23-min exposure to air 
followed by a 7-min exposure to 5% COs in air. Respiration 
[frequency (f) and tidal volume (Vv)] was monitored continuously 
and data are reported for the last 3 min of exposure to air and the 
last 3 min of exposure to COs. Increasing doses of drug were 
administered SC during the first minute of consecutive timeouts with 
the cumulative dose increasing by 0.5 log units per cycle. Compound 
28 was studied up to doses that decreased respiratory function 
to < 60% of control. To determine whether respiratory depressant 
effects of compound 28 were mediated by opioid receptors, a dose- 
effect determination was repeated for compound 28 beginning 
30 min after SC injection of various doses of quadazocine. 
Drugs 
The drugs used in these studies were morphine sulfate (Mallinck- 
rodt, Inc., St Louis, MO), naltrexone hydrochloride (Endo Labora- 
tories, Inc., Garden City, NY), alfentanil hydrochloride (Janssen 
Pharmaceutica, Piscataway, N J), quadazocine methanesulfonate 
(WIN 44,441; Sterling-Winthrop, Rensselaer, NY), and ethylketo- 
cyclazocine methanesulfonate (EKC; Sterling-Winthrop, Ren- 
sselaer, NY). Compound 28 was synthesized by one of the authors 
(MRS) according to the procedures of Bagley et al. (1989). 
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Data analyses 
Results of drug self-administration studies are rates of lever pressing 
expressed in responses per second as a function of dose (mg/kg body 
weight/injection). Results from drug discrimination studies are 
expressed as the average percentage of responses on the drug lever 
[% drug responding (%DR)] +_ t SEM and are plotted as a 
function of dose. Compound 28 was considered to have substituted 
for a training compound if it produced an average of _> 90% 
responding on the drug-associated lever. The dose of compound 28 
required for 50% effect (Aso) in monkeys discriminating between 
saline and naltrexone was estimated from control (no antagonist) 
dose-effect curves and from each dose-effect curve determined in the 
presence of various doses of naltrexone or quadazocine. The log of 
[dose ratio (As0 with antagonist (A')/Aso without antagonist (A)) 
- 1] was plotted as a function of the negative log dose of antagonist 
(B), i.e., Schild plot (Aruntakshana and Schild 1959). Other analyses 
were also conducted for compound 28 administered in combination 
with either naltrexone or quadazocine with the Schild plot slopes 
constrained to - 1 (Tallarida et al. 1979). Response rate data from 
the drug discrimination study are expressed as the mean response 
rate +_ 1 SEM and calculated as a percentage of the control (no 
drug) response rate. Tail withdrawal latencies are expressed as a 
percentage of the maximum possible effect (20 s) and calculated as: 
[test latency minus control (no drug) latency] divided by (20 minus 
control latency) multiplied by 100. Percentages are plotted as a 
function of dose and represent the average of single determinations 
in each of four subjects _+ 1 SEM. Results from the respiration study 
are presented as the average f and VT _+ 1 SEM expressed as a 
percentage of f and Vx under control (no drug) conditions in 
monkeys breathing air or 5% CO2 in air. 
R e s u l t s  
Self-administration studies 
In all three subjects, increases in the dose of compound 
28 produced increases in rates of self-administration 
responding (Fig. 2). Over the dose range studied, max- 
imum response rates were obtained in all of the subjects 
with a dose of 0.0003 mg/kg of compound 28; larger doses 
of compound 28 (data not shown) maintained rates of 
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Fig. 2. Self administration of compound 28 under control condi- 
tions and in the presence of pretreatment doses of 0.01.or 0.i mg/kg 
quadazocine. Ordinate: averaged rate of lever pressing in responses 
per second. With the exception of results obtained after pre- 
treatment with 0.1 mg/kg quadazocine (n = 2), each point is the 
average of three subjects. Abscissa: dose of compound 28 in mg/kg. 
Data point above S represents the effects of saline. Quadazoeine 
dose (mg/kg): (zS) 0; (©) 0.01; (©) 0A 
lever pressing less than those maintained by 
0.0003 mg/kg. In all three subjects a dose of 0.0003 mg/kg 
alfentanil produced rates of lever pressing (2.30 + 0.54 
responses per second; data not shown) that exceeded 
response rates obtained with any dose of compound 28. 
When saline was substituted for alfentanit rates of respon- 
ding averaged 0.17 +_ 0.06 responses per second. 
The positive reinforcing effects of compound 28 were 
antagonized in a dose-related manner by quadazocine. 
Pretreatment with a dose of 0.01 mg/kg quadazocine 
shifted the compound 28 dose-effect curve slightly (<  3 
fold) to the right and decreased the maximum obtainable 
rate of responding. A 10-fold larger dose of quadazocine, 
0.1 mg/kg, shifted the compound 28 dose-effect curve an 
additional 10-fold to the right and also decreased the 
maximum effect. 
Drug discrimination studies 
The administration of increasing doses of alfentanil pro- 
duced dose-related generalization to the drug-associated 
lever in subjects discriminating between saline and alfen- 
tanil with complete generalization (i.e., _> 90% respon- 
ding on the drug lever) occurring with doses of alfentanil 
larger than 0.0056 mg/kg (diamonds, upper left panel, 
Fig. 3). Compound 28 produced a dose-related switch in 
responding from the saline lever to the alfentanil lever 
with complete generalization occurring with doses of 
compound 28 larger than 0.001 mg/kg (triangles, upper 
left panel, Fig. 3). Atfentanil and compound 28 produced 
only small decreases in response rate at doses which 
occasioned responding on the drug lever (lower left panel). 
Administration of increasing doses of EKC produced 
dose-related generalization to the drug-associated lever in 
subjects discriminating between saline and EKC with 
complete generalization occurring with doses of EKC 
larger than 0.00t mg/kg (squares, upper right panel, 
Fig. 3). In contrast to the complete substitution obtained 
with compound 28 in monkeys discriminating between 
saline and alfentanil, compound 28 produced only saline- 
lever responding, up to a dose of compound 28 that 
eliminated responding (0.01 mg/kg), in monkeys discrim- 
inating between saline and EKC. Monkeys discriminating 
saline from EKC appeared to be more sensitive to the 
rate-decreasing effects of compound 28 as compared to 
monkeys discriminating saline from alfentanil (compare 
triangles, lower panels, Fig. 3). 
In monkeys receiving daily injections of morphine 3 h 
prior to experimental sessions, increasing doses of naltrex- 
one produced a dose-related switch in responding from 
the saline lever to the naltrexone lever with complete 
generalization occurring with doses of naltrexone larger 
than 0.0032 mg/kg (circles, upper left panel, Fig. 4). Up to 
a dose that eliminated responding (0.32 mg/kg), com- 
pound 28 failed to produce any responding on the naltrex- 
one-associated lever in morphine-treated monkeys (trian- 
gles, left panels, Fig. 4). Doses of compound 28 that 
eliminated responding maintained by food presentation in 
monkeys discriminating between saline and EKC had no 
effect on responding maintained by stimulus-shock ter- 
mination in morphine-treated monkeys discriminating 
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Fig. 3. Discriminative stimulus effects and response rate 
effects of compound 28 in separate groups of rhesus 
monkeys discriminating between saline and either 
0.0056 mg/kg alfentanil (n = 2; left panels) or 
0.0032 mg/kg EKC (n = 2; right panels). Ordinates: upper 
panels, percentage of responses on the drug lever [drug 
responding (%DR)] _+ 1 SEM; lower panels, averaged rate 
of lever pressing on bdth levers expressed as a percentage 
of response rates under control (no drug) conditions, 
Abscissae: dose in mg/kg body weight. Data points above 
S represent the effects of a SC injection of saline. (O) 
Alfentanil; (zS) compound 28; ([Z) ethylketocyclazocine 
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Fig. 4. Discriminative stimulus effects and response rate effects of 
compound 28 in three morphine-treated monkeys discriminating 
between saline and 0.01 mg/kg of naltrexone: left panel, effects of 
compound 28 and naltrexone in subjects that received 3.2 mg/kg 
morphine 3 h earlier (i.e., morphine condition); right panel, effects of 
compound 28 and alfentanil in subjects that received morphine 
27 h earlier and saline 3 h earlier (i.e., saline condition). Data points 
above S indicate the effects of saline under each of the two 
treatment conditions. See Fig. 3 for other details (O) Alfentanil; 
(A) compound 28; (O) naltrexone 
between saline and naltrexone (triangles, lower right panel 
of Fig. 3 and lower left panel of Fig. 4, respectively). 
When saline was substituted for the daily injection of 
morphine, subjects responded exclusively on the naltrex- 
one lever (point above S, upper right panel, Fig. 4). Alfen- 
tanil attenuated the naltrexone-lever responding that oc- 
curred in saline-treated (morphine-abstinent) monkeys 
with complete attenuation ( <  10% responding on the 
naltrexone lever) occurring with a dose of 0.032 mg/kg 
alfentanil. Compound 28 also reversed naltrexone lever 
responding and was equipotent to alfentanil in this regard 
(compare diamonds and triangles, upper right panel, 
Fig. 4). 
The alfentanil-like discriminative stimulus effects of 
compound 28 observed in morphine-abstinent (saline- 
treated) monkeys (i.e., reversal of naltrexone lever respon- 
ding) was antagonized by the opioid antagonists naltrex- 
one and quadazocine (Fig. 5). Under control conditions, a 
dose of 0.032 mg/kg of compound 28 reversed completely 
naltrexone lever responding (triangles, upper panels, 
Fig. 5). In contrast, when subjects had received either 
0.032mg/kg naltrexone (squares, upper left panel) or 
0.1 mg/kg quadazocine (diamonds, upper right panel), a 
dose of 1.0 mg/kg of compound 28 was required to reverse 
completely naltrexone lever responding. From dose-effect 
curves determined for compound 28 in combination with 
naltrexone or quadazocine, Schild plots were constructed 
(lower panels, Fig. 5) and apparent affinity estimates were 
calculated using pAz analyses. The pA2 values for naltrex- 
one and quadazocine were: 8.26 and 7.85, respectively, 
with unconstrained slopes; 8.41 and 7.87, respectively, 
when slopes were constrained to - 1. Apparent affinities 
for naltrexone and quadazocine in combination with com- 
pound 28 were similar to apparent affinities for the same 
antagonists administered in combination with other 
agonists (Table 1). 
Analgesia studies 
Under control conditions the average latency for monkeys 
to remove their tails from warm water was 20 + 0, 0.86 
+_ 0.08, and 0.65 + 0.09 s for 40, 50 and 55°C, respect- 
ively. Compound 28 increased in a close-related manner 
the latency for monkeys to remove their tails from warm 
(50 or 55°C) water (Fig. 6), producing latencies that 
were _> 90% of the maximum possible effect (i.e., 20-s 
latencies) at a dose of 0.178 mg/kg (50 ° C, left panel; 55 ° C, 
right panel). The analgesic effects of compound 28 were 
antagonized in a dose-related manner by quadazocine 
(Fig. 6). The analgesia dose-effect curves for compound 28 
were shifted 3-fold to the right after pretreatment with 
0.1 mg/kg quadazocine; pretreatment with a dose of 
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Fig. 5. Dose-eflbct curves for compound 28 administered alone and 
in combination with various doses of either nattrexone (/eft panel) 
or quadazocine (right panel) in three monkeys discriminating be- 
tween saline and 0.01 mg/kg naltrexone. Subjects received 
3.2 mg/kg morphine 27 h earlier and saline 3 h earlier. Antagonists 
were administered 15 min prior to the first injection of compound 
28. See Figs 3 and 4 for other details. Antagonist dose (mg/kg): (~) 
0; (O) 0,01; (ILl) 0.032; (O) 0.1; (V),I.0 
1.0 mg /kg  quadazocine resulted in antagonism that was 
not surmounted by compound 28 up to the maximum 
dose that could be studied, 1.78 mg/kg.  
Respiration studies 
Table 2 shows the average frequency (f) and tidal volume 
(VT) of respiration for three monkeys breathing normal air 
or 5% COz in air. Exposure to COz increased the average 
f and VT to 142.8 _+ 2.8% and 120.9 __ 6.5% of control, 
respectively. Compound  28 decreased f and VT in a dose- 
related manner in subjects breathing air and in subjects 
breathing 5% CO 2 in air (Fig. 7). A dose of 0.001 mg /kg  
of compound 28 had little or no effect on f or V T with 
larger doses producing progressively larger decreases in 
both measures of respiratory function. At the largest dose 
studied, 0.1 mg/kg,  l a n d  V T were decreased to < 50% of 
control under both conditions (air and CO2). 
The respiratory depressant effects of compound 28 
were attenuated in a dose-related manner  by quadazocine 
(Fig. 8). Pretreatment with a dose of 0.01 m g / k g  quadazo- 
T a b l e  1. Apparent atfinity estimates for naltrexone and quadazo- 
cine in combination with compound 28, alfentanil and morphine in a 
drug discrimination procedure 
Agonist Nattrexone Quadazocine 
pA 2 (slope) pA2 (slope) 
Compound 28 8.26 ( -  1.14)" 7.85 ( -  1.02) 
AlfentaniP 8.69 ( -  0.97) 7.55 ( -  1.14) 
Morphine ~ 8.32 ( -  1.04) c 
" Apparent affinity using the method of Arunlakshana and Schild 
(1959) 
b From France et at. (1990a) 
° Not studied 
T a b l e  2. Control (no drug) frequency (f) and tidal volume (VT) of 
respiration for monkeys breathing air or 5% CO 2 in air 
Subject Air 5% CO 2 
f" VUT P V} 
RE 34 56.5 48 63.5 
SA 23 94.9 32 126.8 
EL 27 77.2 40 90.0 
Frequency of respiration in breaths/min 
Volume of respiration in ml/inspiration 
cine shifted the f and VT dose-effect curves 2-3 fold to the 
right of control dose-effect curves. Larger doses of quad- 
azocine produced further shifts to the right in the com- 
pound 28 dose-effect curves. For example, under control 
conditions a dose of 0.1 mg/kg  of compound 28 decreased 
V-r to < 50% of control; in the presence of 1.0 mg /kg  
quadazocine VT was _> 85% of control up to a dose of 
1.0 mg /kg  of compound 28 (right panel, Fig. 8). Qualitat- 
ively similar effects were obtained for quadazocine in 
combination with compound 28 in monkeys breathing air 
(data not shown). 
D i s c u s s i o n  
Several clinically useful compounds have been developed 
from the 4-[heteroanilido]piperidine series, including 
fentanyl, sufentanil, and alfentanil. All three of these com- 
pounds share many effects with morphine, including pro- 
found respiratory depressant effects at large doses. The 
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Fig. 6. Effects of compound 28 on tail withdrawal 
latencies under control conditions (triangles) and in the 
presence of 0.1 (O) or 1.0 mg/kg (V) quadazocine 
from 50 and 55°C water (/eft and right panels, 
respectively). Ordinates: average tail withdrawal 
latencies __ 1 SEM are expressed as a percentage of the 
maximum possible effect (i.e., 20 s) for four monkeys. 
Abscissae: dose of compound 28 in mg/kg body 
weight. Data points above C represent the effects of 
saline or quadazocine prior to administration of 
compound 28 
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Fig. 7. Effects of compound 28 on respiratory function (fand VT) in 
three monkeys breathing air (left panel) or breathing 5% CO2 in air 
(right panel). Ordinates: averaged f and V r expressed as a percent- 
age of f and VT, respectively, under the corresponding condition 
(air or CO2) in the absence of drug (C; 100%). Abscissae: dose of 
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Fig. 8. Antagonism by quadazocine of the respiratory depressant 
effects of compound 28. Dose-effect curves were determined for 
compound 28 under control conditions (triangles) and beginning 
30 min after an acute injection of quadazocine (0.01-1.0 mg/kg). 
See Fig. 7 for other details. Quadazocine dose (mg/kg): (2x) 0; (@) 
0.01; (O) 0.1; (V) t.0 
novel profile of action reported for mirfentanit (Bagley 
et al. 1989; France et al. 1991), therefore, was particularly 
interesting because there had not been any previous re- 
port of compounds from the fentanyl series which had 
opioid antagonist actions. In the present study another 
fentanyl derivative, compound 28, was studied to see 
whether it might also exert opioid antagonist or non- 
opioid agonist actions in rhesus monkeys. However, in 
contrast to the low efficacy opioid agonism observed for 
mirfentanil, compound 28 had agonist effects under all 
experimental conditions. Moreover, all of these agonist 
effects were antagonized by quadazocine. Thus, compared 
to mirfentanil, compound 28 appears to have considerably 
higher efficacy at IX receptors. 
The effects of some fentanyl derivatives appear to be 
quite varied among different species. For example, in rats, 
rabbits, and mice both mirfentanil and compound 28 had 
limited opioid agonists actions and, under some condi- 
tions, had opioid antagonist actions (Bagley et al. 1989). 
Second, there was no report of any nonopioid (i.e., nalox- 
one-insensitive) effects for either of these compounds in 
non-primate species. Mirfentanil also was reported to be 
more effective than compound 28 in producing analgesic 
effects in non-primate species. In contrast to results ob- 
tained in other species, in rhesus monkeys compound 28 
was a potent, efficacious morphine-like agonist with no 
apparent nonopioid effects. The profile of action obtained 
with compound 28 in rhesus monkeys was qualitatively 
the same as that obtained with alfentanil under the same 
conditions. Together with results obtained in several dif- 
ferent species for mirfentanil, results from the current 
study on compound 28 suggest pharmacological effects of 
fentanyl derivatives, and perhaps other compounds, in 
mice, rats or rabbits cannot be assumed to predict their 
effects in other species. 
Sensitivity to rate-decreasing effects of compound 28 
varied markedly among different groups of monkeys. For 
example, morphine-treated monkeys discriminating be- 
tween saline and naltrexone were 30 times less sensitive to 
the rate-decreasing effects of compound 28 than monkeys 
discriminating between saline and EKC. This difference in 
sensitivity was not simply the result of different schedule 
conditions between the two groups (food versus stimulus- 
shock termination) as monkeys discriminating between 
saline and alfentanil under a food schedule were also less 
sensitive to the rate-decreasing effects of compound 28. 
Moreover, doses of compound 28 that were studied for 
discriminative stimulus effects in morphine-treated mon- 
keys (> 0.01 mg/kg) could not be studied in other ex- 
periments because of the profound respiratory-depressant 
effects of these doses in untreated subjects (see Fig. 8). 
Thus, cross tolerance to compound 28 was evident only in 
subjects that frequently received morphine or morphine- 
like agonists, providing further evidence of the Ix agonist 
mechanism of action for compound 28 in rhesus monkeys. 
The selectivity and potency of opioid antagonists in 
preventing the effects of different opioid agonists has been 
used widely to differentiate receptor mechanisms. One 
quantitative method that has been used to analyze be- 
havioral effects of opioids involves apparent affinity estim- 
ates for selective antagonists (e.g., Takemori 1974). The 
apparent affinity estimates for naltrexone were similar 
regardless of whether the agonist was alfentanil (pA 2 
= 8.69; France et al. 1990a), morphine (pA 2 = 8.32; 
France et al. 1990a) or compound 28 (pA 2 = 8.26; present 
study); similarly, the pA 2 values for quadazocine were 7.55 
in combination with alfentanil (France et al. 1990a) and, in 
the present study, 7.85 in combination with compound 28. 
The similarity of pA 2 values obtained for naltrexone and 
for quadazocine with compound 28, alfentanil and mor- 
phine, drugs that vary in absolute potency by more than 
170 fold, strongly supports the notion that all three 
compounds exert their discriminative stimulus effects at 
the same receptor (i.e., IX). Moreover, the striking similarity 
among these in vivo apparent affinity estimates further 
demonstrates the utility of this quantitative approach for 
differentiating receptor-mediated behavioral effects 
(Takemori 1974; Bertalmio and Woods 1987; Dykstra et 
al. 1987). 
Although results from the present studies do not 
provide any direct evidence for a nonopioid effect of 
compound 28, it is possible that compound 28 might have 
nonopioid effects that are masked by opioid effects. For 
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example, decreases in maximum rates of self administra- 
tion of compound 28 when subjects received a large dose 
of an opioid antagonist (i.e., quadazocine) might have 
resulted from an unmasking of a nonopioid, and non- 
reinforcing, effect of compound 28. Whereas the self ad- 
ministration dose-effect curve for alfentanil, a compound 
for which nonopioid actions have not been demonstrated, 
was shifted 30-300 fold to the right by quadazocine 
with little change in the maximum rate of responding 
(Bertalmio and Woods 1989; G. Winger, unpublished 
observation), the self-administration dose-effect curve for 
mirfentanil, a compound for which nonopioid actions 
have been demonstrated, first was shifted 3-fold to the 
right by quadazocine then shifted down with a decrease of 
more than 50% in the maximum rate of responding 
(France et al. 1991). Additional studies with compound 28, 
particularly in the presence of large doses of opioid antag- 
onists, might unmask a mirfentanil-like, nonopioid action 
for compound 28. 
The results obtained in the current study with the 
fentanyl derivative compound 28 (Bagley et al. 1989) 
demonstrate that a small modification in the structure of 
rnirfentanil confers strong ~t agonism, which appears to 
either occur in the absence of, or prevent the expression of, 
the nonopioid actions observed for mirfentanil (France 
et al. 1991). Further studies on the structure-activity rela- 
tions of other fentanyl derivatives might provide import- 
ant insights in to the physicochemical requirements for 
efficacy at the g opioid receptor. 
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